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Abstract
Human pluripotent stem cells (hPSCs) represent a prime cell source for pharmacological research and regenerative
therapies because of their extensive expansion potential and their ability to differentiate into essentially all somatic
lineages in vitro. Improved methods to stably introduce multiple transgenes into hPSCs will promote, for example,
their preclinical testing by facilitating lineage differentiation and purification in vitro and the subsequent in vivo
monitoring of respective progenies after their transplantation into relevant animal models. To date, the estab-
lishment of stable transgenic hPSC lines is still laborious and time-consuming. Current limitations include the low
transfection efficiency of hPSCs via nonviral methods, the inefficient recovery of genetically engineered clones,
and the silencing of transgene expression. Here we describe a fast, electroporation-based method for the gener-
ation of multitransgenic hPSC lines by overcoming the need for any preadaptation of conventional hPSC cultures
to feeder-free conditions before genetic manipulation. We further show that the selection for a single antibiotic
resistance marker encoded on one plasmid allowed for the stable genomic (co-)integration of up to two additional,
independent expression plasmids. The method thereby enables the straightforward, nonviral generation of valuable
multitransgenic hPSC lines in a single step. Practical applicability of the method is demonstrated for antibiotic-
based lineage enrichment in vitro and for sodium iodide symporter transgene-based in situ cell imaging after
intramyocardial cell infusion into explanted pig hearts.
Introduction
Human pluripotent stem cells (hPSCs) includingembryonic stem cells (hESCs) and induced pluripotent
stem cells (hiPSCs) are considered a prime cell source for
envisioned regenerative therapies because of their extensive
proliferation and multilineage differentiation potential
in vitro. To date, such cell-based approaches are still under
development and numerous issues remain to be solved before
hPSC-derived progenies can enter routine clinical applica-
tions. Stable transgene-expressing hPSC lines can be valu-
able tools along this path. For example, the overexpression of
specific transcription or growth factors aiming at the directed
differentiation into a desired cell type may overcome poor
differentiation efficiencies that exist for several somatic lin-
eages (David et al., 2009; Hartung et al., 2013). On the other
hand, lineage-restricted reporter gene expression could be
used to enrich for specific progenies (Boecker et al., 2004;
Huber et al., 2007; Xu et al., 2008b; Kita-Matsuo et al., 2009;
Ritner et al., 2011). Another application is the cell type-
specific or ubiquitous expression of marker genes to monitor
cell engraftment in respective animal models post-
transplantation (Dai et al., 2007; Sun et al., 2009; Mauritz
et al., 2011).
A multitude of methods to genetically manipulate hPSCs
have been established including viral transduction ( Jang
et al., 2006; Wurm et al., 2011), chemical transfection (Liu
et al., 2009), and electroporation (Zwaka and Thomson,
2003; Costa et al., 2005). Among integrating vector systems
that could be used for the generation of stable transgenic
PSC lines, classical oncoretroviral vectors are well known to
become silenced in pluripotent stem cells (Yao et al., 2004).
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Although great transduction efficiencies of > 90% and high
transgene expression levels can be achieved by lentiviral
vectors (Ma et al., 2003; Moore et al., 2005), murine and
human PSCs were found to substantially suppress long-term
expression of transgenes delivered by these vector systems
(Cherry et al., 2000; Xia et al., 2007). This effect becomes
manifested mainly during the first days after transduction
and appears to depend on the type of viral promoter used
and the site of transgene integration into the genome as well
(Haas et al., 2000; Philippe et al., 2006; Xia et al., 2007;
Norrman et al., 2010). Another objection is the tendency of
integrating viral vectors to induce insertional mutagenesis
that provokes oncogene activation or inactivation of tumor
suppressor genes (Kustikova et al., 2005), thereby increas-
ing the likelihood of malignant cell transformation. In
contrast to plasmid vectors generated in bacteria, the pro-
duction of viral vectors is also more time-consuming and
requires higher safety levels.
Common techniques for the introduction of plasmid-
based expression vectors into mammalian cells include
electroporation and chemical transfection with liposomes, or
polycationic complexes, being the most frequently used
agents to facilitate cell entry (Pichon et al., 2010; Ziello
et al., 2010). The development of improved transfection
reagents such as FuGENE HD or GeneJammer, for example,
allowed the generation of genetically engineered hPSC
clones (Braam et al., 2008a; Liu et al., 2009), but effi-
ciencies were relative low (Liu et al., 2009) and cell line
dependent.
During electroporation a transient permeabilization of the
plasma membrane occurs, thereby enforcing the uptake of
exogenous nucleic acid molecules into the cell, which is in
principle not limited by the size and nature of a vector
(Moore et al., 2005). However, although the successful
electroporation-based genetic modification of semidissociated
‘‘hPSC clumps’’ was achieved (Zwaka and Thom-
son, 2003), the method ideally requires dissociation into a
single-cell suspension to substantially increase the trans-
fection efficiency (Schinzel et al., 2011). In contrast to
pluripotent mouse cells, human PSCs are highly sensitive
to complete dissociation, resulting in dramatically reduced
survival rates after electroporation. Prior approaches have
tried to tackle this issue by adapting hPSCs to feeder-free
conditions, which were established by trypsin-dependent
cell dissociation for several passages before transfection.
This approach, however, may lead to an inadvertent, clonal
preselection of cells adapted to this treatment, thus re-
quiring a frequent assessment of pluripotency and karyo-
typing (Braam et al., 2008a). The adaptation procedure is
also time-consuming, thereby extending the generation of
transgenic lines for several weeks (Costa et al., 2007;
Braam et al., 2008b).
Here we describe a straightforward approach for the
rapid, relative efficient, and simultaneous introduction of
several plasmid vectors into hPSCs. Stable multitransgenic
clones were established by means of single drug resistance
encoded on only one of these expression vectors. The
method is applicable directly to conventional feeder-based
cultures and does not require any preadaptation to single-
cell passaging. Multitransgenic hPSC lines were established
carrying stably integrated (1) fluorescence-emitting report-
ers, (2) a sodium iodide symporter (NIS) facilitating non-
invasive in vivo cell tracking (Acton and Kung, 2003;
Templin et al., 2012), and (3) antibiotic resistance genes
controlled by ubiquitous or lineage-specific promoters. We
show that the transgenic lines resulting from our approach
maintain their pluripotency and differentiation potential and
retain a normal karyotype. In numerous clones the reporter
gene expression was found to be stable after extensive
passaging in the undifferentiated state, even if transgenes
were encoded on cointroduced plasmids carrying no addi-
tional antibiotic resistance marker. Finally, the possibility of
NIS-dependent in situ imaging after intramyocardial infu-
sion of radionuclide-labeled cells was demonstrated and
antibiotic-based purification of cardiomyocytes (CMs) was
performed to demonstrate the broad practical applicability
of the method.
Materials and Methods
Feeder-dependent adherent culture
Human ES cell lines hES3 (Reubinoff et al., 2000) and I3
(Amit and Itskovitz-Eldor, 2002), as well as the three human
iPSC lines hCBiPS2 (cord blood endothelial cell derived;
Haase et al., 2009), hFF1-iPS4 (human foreskin fibroblast
derived), and hHSC_F1285_T-iPS2 (hematopoietic stem
cell derived; Hartung et al., 2013), were cultured on irra-
diated murine embryonic fibroblasts (MEFs) in 80%
KnockOut DMEM (Dulbecco’s modified Eagle’s medium)
supplemented with 20% KnockOut Serum Replacement,
1mM l-glutamine, 0.1mM 2-mercaptoethanol, 1% nones-
sential amino acid stock (all from Life Technologies,
Karlsruhe, Germany), and basic fibroblast growth factor
(bFGF) at either 50 ng/ml (hES3, I3) or 4 ng/ml (hiPSCs)
(supplied by the Institute for Technical Chemistry, Leibniz
University Hannover, Hannover, Germany) (Chen et al.,
2012). Cells were cultured in 6-well plates and passaged
once per week with collagenase type IV (1mg/ml; Invitro-
gen). The medium was changed daily.
Feeder-independent adherent culture
For the transfer of hESCs to feeder-independent culture
conditions, cells were detached from MEFs, using collage-
nase type IV (1mg/ml). After washing once with phosphate-
buffered saline (PBS) without Ca2 + /Mg2 + the cells were
dissociated into single cells, using Accutase (PAA Labora-
tories, Co¨lbe, Germany). hESCs were seeded at 1.25 · 106
per 25 cm2 flask in MEF-conditioned medium (Burridge
et al., 2011) and passaged twice per week. The medium was
changed daily.
Plasmid vectors
The vector aMHCneoPGKhygro is a 10.9-kb construct
carrying two selection cassettes: (1) the hygromycin resis-
tance gene (hygroR) under the control of the ubiquitous
phosphoglycerate kinase (PGK) promoter, allowing the es-
tablishment of stable integrants; and (2) the neomycin re-
sistance gene (neoR) under the control of the heart-specific
a-myosin heavy chain (aMHC) promoter, allowing the
selection of hPSC-derived cardiomyocytes (Klug et al.,
1996). Reporter gene constructs are based on CAG-eGFP
(5.5 kb) with transgene expression controlled by the chicken
b-actin (CBA) promoter combined with the human
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immediate-early cytomegalovirus (CMV-IE) enhancer (to-
gether termed the CAG promoter). CAG-nRedStar (5.6 kb)
was constructed by replacing enhanced green fluorescent
protein (eGFP) with red fluorescent protein (RedStar) in
CAG-eGFP (Knop et al., 2002) coupled to a nuclear
membrane location signal (nucmem, nRedStar) (Okita et al.,
2004). The bicistronic vector CAG-rNIS-nVenus contains
the rat sodium iodide symporter (rNIS) (Templin et al.,
2012) coupled to the yellow nucleus-located fluorescent
reporter Venus (nVenus) by an internal ribosomal entry site
(IRES2).
Cell transfection and generation of transgenic clones
All transfections were performed with the Neon system
(Life Technologies). Several enzyme combinations were
tested for cell harvesting. These included treatment with
collagenase IV (Life Technologies) to remove the cells from
their feeder layer, followed by an additional incubation step
with collagenase B (Roche, Mannheim, Germany) or Try-
pLE (Life Technologies) for single-cell dissociation ac-
cording to the manufacturers’ specifications. In the final
protocol the combination of collagenase IV and TrypLE was
used. For single-cell preparation, 0.2% collagenase IV was
added directly to the cell cultures and incubated for 5min at
37C. After centrifugation cells were washed once with PBS
without Ca2 + /Mg2 +and incubated with 0.5ml of TrypLE
for 3min at 37C. The cells were counted in PBS without
Ca2 + /Mg2 + in a Thoma hemocytometer, and 1.5 · 106 dis-
sociated single-cell hPSCs were pelleted at 1000 rpm for
5min, resuspended in 110ll of resuspension buffer R, and
transferred with the corresponding circular plasmid DNA
into sterile microcentrifuge tubes. The cells were electro-
porated with two pulses at 1000V for 20msec and plated
onto Matrigel-coated 6-cm dishes in preincubated condi-
tioned medium supplemented with 10 lM ROCK (Rho-as-
sociated coiled-coil kinase) inhibitor (Y-27632; supplied by
the Institute for Organic Chemistry, Leibniz University
Hannover) (Palecek et al., 2011). Plasmids were used in
their circular form without prior linearization and were ap-
plied in equimolar amounts without exceeding 20lg of total
DNA per electroporation sample. Cell counts were per-
formed directly after electroporation and on plated cells
48 hr after transfection by means of trypan blue exclusion in
a Thoma hemocytometer; respective viable cell counts were
compared with the cell number applied for transfection (i.e.,
1.5 · 106 per sample) to calculate the percentage of cell
viability/recovery. Forty-eight hours after electroporation
the transient transfection efficiencies were determined for
eGFP or nRedStar by flow cytometry. On parallel dishes, at
48–72 hr after transfection, hygromycin (Invitrogen) was
added at 50 lg/ml (hESCs) or 200lg/ml (hiPSCs) to select
for stable transgenic clones. Overall, cells were incubated
for 4 days in the presence of hygromycin, with the selection
medium replaced once after 48 hr. Upcoming colonies were
manually picked*14 days after electroporation, transferred
onto irradiated feeder cells, and expanded clonally.
Characterization of multitransgenic clones
and cell lines
Established clones and cell lines derived therefrom were
analyzed for the expression of typical pluripotency-associated
markers via immunofluorescence staining. PCR was applied
to test for the genomic integrity of the plasmid aMHCneo-
PGKhygro (see primer sequences in Supplementary Table
S1; supplementary data are available online at http://online
.liebertpub.com/hgtb) in cells five passages after clone
picking. Stable expression of fluorescence reporter genes in
undifferentiated cell lines was monitored by flow cytometry
for up to 23 passages after clone picking and at respective
time points after initiation of differentiation, as indicated in
Results.
Southern blot analyses
Ten micrograms of genomic DNA was cleaved with en-
donucleases as indicated in Results, separated on a 0.8%
TAE (Tris–acetate–EDTA)–agarose gel; transferred onto
Biodyne B nylon membrane (Pall Life Sciences, Dreieich,
Germany); and hybridized with radiolabeled probes, using a
DecaLabel kit (Fermentas, St. Leon-Rot, Germany). The
hybridization probe for eGFP was an 807-bp EcoRI–BglII
fragment from pCAGGS2, and for neoR a 915-bp HindIII–
SacI fragment isolated from aMHCneoPGKhygro.
Karyotype analyses
After trypsinization, metaphases were prepared according
to standard procedures. Fluorescence R-banding using
chromomycin A3 and methyl green was performed as de-
scribed in detail previously (Schlegelberger et al., 1999). At
least 15 metaphases were analyzed for each clone. Kar-
yotypes were described according to the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN).
Induction of hPSC differentiation,
cardiomyocyte selection, and quantification
To induce embryoid body (EB) formation of transgenic
cell lines, undifferentiated cells were washed with a chem-
ically defined serum-free (SF) medium and subsequently
were mechanically harvested. Resulting cell clumps were
transferred to ultralow attachment 6-well plates (Greiner
Bio-One, Frickenhausen, Germany) and cultured in SF
supplemented with 10lM SB203580 (Graichen et al., 2008;
Xu et al., 2008a). The medium was replaced every second
day. Flow cytometry was performed to quantify the amount
of eGFP-expressing cells and the presence of cardiomyo-
cytes, which was tested by the expression of the intracellular
cardiac-specific isoform troponin T (cTnT; see experimental
details below). Selection of cardiomyocytes was initiated by
the addition of Gibco G418 (200lg/ml; Invitrogen) 2 days
after the first beating foci were observed. Antibiotic selec-
tion was retained for at least 7 days (Xu et al., 2008b). To
assess the moiety of cTnTpos cardiomyocytes, cell samples
were fixed on the dish with 4% paraformaldehyde (Sigma-
Aldrich, St. Louis, MO) for 20min and blocked with Tris-
buffered saline plus 5% donkey serum and 0.25% Triton
X-100 (Sigma-Aldrich) for 20min at room temperature. To
analyze the expression of cTnT, respective primary and
secondary antibodies (1:200 anti-Troponin T, cardiac iso-
form Ab-1, mouse monoclonal IgG [Thermo Scientific,
Karlsruhe, Germany] and 1:200 donkey anti-mouse IgG
labeled with DyLight 549 [Jackson ImmunoResearch La-
boratories, West Grove, PA]) were diluted in PBS without
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Ca2 + /Mg2 + , supplemented with 1% bovine serum albumin
(BSA; Sigma-Aldrich), and incubated for 1 hr at room
temperature. For quantification, samples were photographed
at appropriate magnification and the total number of 4¢,6-
diamidino-2-phenylindole (DAPI)-stained nuclei was de-
termined versus the number of cTnTpos cells.
Flow cytometry
To assess eGFP or nRedStar expression cells were washed
with PBS without Ca2+ /Mg2+ and dissociated by treatment
with trypsin for 3min at 37C to create a single-cell sus-
pension. Cells were resuspended in PBS without Ca2+ /Mg2+
and analyzed on a FACSCalibur system (BD Biosciences,
San Jose, CA) by applying BD CellQuest software (BD
Biosciences). Nontransgenic hPSCs served as control.
To analyze the expression of cTnT in differentiated cells,
cultures were dissociated with collagenase B, following cell
fixation and permeabilization with a Fix&Perm cell per-
meabilization kit (Dianova, Hamburg, Germany) and incu-
bated with respective antibodies (1:200 anti-TnT, cardiac
isoform Ab-1, mouse monoclonal IgG [Thermo Scientific]
and 1:200 donkey anti-mouse IgG labeled with DyLight 549
[Jackson ImmunoResearch Laboratories]) according to the
manufacturers’ specifications. Stained cells were analyzed
by flow cytometry, using a BD Accuri C6 (BD Biosciences),
and data were analyzed with FlowJo software (Treestar,
Ashland, OR).
Immunohistological staining
Undifferentiated as well as differentiated cells were fixed
with 4% paraformaldehyde, washed with PBS, and treated
with 5% donkey serum, 0.25% Triton X-100 diluted in Tris-
buffered saline (TBS) for 20min at room temperature. After
rinsing, the cells were incubated for at least 1 hr with re-
spective primary antibodies (1:300 anti-a-fetoprotein, mouse
IgG1 [R&D Systems, Minneapolis, MN]; 1:400 anti-b-tubulin,
mouse IgG2a [Millipore, Darmstadt, Germany]; 1:100 anti-
GFP [cross-reacting with Venus] goat IgG [Acris, Herford,
Germany]; 1:100 anti-OCT4 mouse IgG [Santa Cruz Bio-
technology, Santa Cruz, CA]; 1:200 anti-SOX17, goat IgG
[R&D Systems], 1:100 anti-SSEA-3 mouse IgM [Develop-
mental Studies Hybridoma Bank, Iowa City, IA]; 1:70 anti-
SSEA-4 mouse IgG [Developmental Studies Hybridoma
Bank]; 1:100 anti-TRA-1-60 mouse IgM [Abcam, Cam-
bridge, MA]; 1:100 anti-Troponin T, mouse IgG [Thermo
Scientific]) diluted in PBS–1% BSA. Further incubation was
performed with the respective secondary antibody (1:200
donkey anti-mouse IgG labeled with DyLight 549, 1:200 don-
key anti-mouse IgG labeled with DyLight 488, 1:200 donkey
anti-mouse IgM labeled with Cy3, and 1:100 donkey anti-goat
IgG labeled with Cy2; all from Jackson ImmunoResearch
Laboratories) for 30min. Cells were rinsed, counterstained
with DAPI (Sigma-Aldrich), and analyzed with an Axio
Observer A1 fluorescence microscope (Carl Zeiss Micro-
Imaging, Goettingen, Germany). For the detection of nVe-
nuspos cells, pig heart tissue was embedded in Tissue-Tek
(Sakura Finetek, Alphen aan den Rijn, The Netherlands)
directly after the injection of 1 · 106 undifferentiated
hCBiPS2 CAG-rNIS6 and stored at - 80C. Subsequently,
10 lm cryosections were generated with a Microm Cryostat
HM 560 cryotome (Thermo Scientific).
Analysis of mRNA expression by qRT-PCR
Total RNA was prepared with an RNeasy kit (Macherey-
Nagel, Du¨ren, Germany) and reverse transcribed with Su-
perScript II (Life Technologies) using oligo(dT) primers
according to the manufacturer’s instructions. Quantitative
RT-PCR (qRT-PCR) was performed in triplicate, using a
Mastercycler ep realplex2 (Eppendorf, Hamburg, Germany)
and ABSOLUTE QPCR SYBR green mix (ABgene, Epsom,
Surrey, UK). The size of amplicons and the absence of non-
specific products were controlled by melting curves. Se-
quences of primers are shown in Supplementary Table S2.
Relative changes in gene expression were analyzed via 2-DDCt
(Livak and Schmittgen, 2001) by comparing transgenic
versus control cells, using Mastercycler ep realplex2 soft-
ware version 2.0 (Eppendorf). Expression levels of target
genes were normalized to b-actin; means – SEM of nor-
malized gene expression levels are presented.
Ex vivo cardiac SPECT-CT imaging
NISpos-hPSCs (1· 106) were incubated for 90min with
1MBq of 123I and vigorously washed, and 5 · 106 labeled
cells were injected into the anterior wall of the left ventricle
of an explanted pig heart, using a NOGA MyoStar intra-
myocardial injection catheter system (Biosense Webster/
Johnson & Johnson, Diamond Bar, CA). The 123I signal was
visualized through a hybrid SPECT-CT (single-photon
emission computed tomography combined with computed
tomography) camera with semiconductor detector technique
(Discovery NM 570C; GE Healthcare, Piscataway, NJ). To
mimic in vivo signal attenuation, imaging of 123I signals was
performed through a dissected pig chest wall that was placed
above the heart.
Statistical analysis
Results are reported as means and standard deviation of
the mean. p values < 0.01, indicated by double asterisks
(**), were considered significant.
Results
Adaptation-free electroporation of plasmid DNA
into hPSCs results in >60% transient transfection
efficiency accompanied by high cell viability
Common feeder-based hPSC cultures were used without
any preadaptation and cells were routinely passaged weekly.
For electroporation, cells were harvested on day 4 post-
passaging to ensure log-phase growth. Applying pretested
electroporation parameters, a first step of optimization was
implied using various enzyme combinations to detach and
dissociate hPSCs. Investigating collagenase IV, collagenase
B, and TrypLE, best results regarding cell viability and
transfection efficiency were achieved by combining colla-
genase IV followed by TrypLE treatment (data not shown;
see detailed protocol in Materials and Methods). Cell sur-
vival also critically depended on the Rho-associated coiled-
coil kinase (ROCK) inhibitor Y-27632 added to the culture
medium postelectroporation (data not shown). To assess
the transient transfection efficiency, two constitutively ex-
pressed fluorescence reporters (eGFP and nRedStar; Fig.
1A) and five independent hPSC lines (two hESC and three
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FIG. 1. Electroporation-based transfection resulted in good cell viability and reporter gene expression. (A) Schematic
presentation of vector structures used for cell line generation. CAG-eGFP and CAG-nRedStar: constitutive expression of
eGFP or the codon-optimized red GFP variant RedStar fused to a nuclear membrane localization signal (nucmem, nRedStar)
is controlled by the CAG promoter. CAG-rNIS-nVenus: bicistronic vector carrying the rat sodium iodide symporter (rNIS)
linked via an internal ribosomal entry site (IRES2) to the yellow GFP variant Venus (nucmem, nVenus) controlled by the
CAG promoter. aMHCneoPGKhygro: hygromycin resistance gene constitutively expressed under the control of the
phosphoglycerate kinase (PGK) promoter and the neomycin resistance gene under the control of the cardiomyocyte-specific
aMHC promoter. (B) Left: Graph depicting transfection efficiencies at 48 hr postelectroporation as determined via flow
cytometry for CAG-eGFP- and CAG-nRedStar-transfected cells. Right: Fluorescence microscopy of seeded cells. On
average, 44 – 5% eGFPpos and 63– 13% nRedStarpos hCBiPS2 cells (n = 7), 18 – 3% eGFPpos (n = 3) and 38 – 1% nRed-
Starpos hFF1-iPS4 cells (n= 6), as well as 38– 5% eGFPpos hES3 cells (n = 6) were detected. (C) Cell viability directly after
cell dissociation and electroporation revealed 98 – 3% viable hCBiPS2 cells and 97 – 6% viable hES3 cells. The addition of
plasmid DNA led to 96– 8% viable hCBiPS2 cells and 95 – 1% viable hES3 cells as assessed by trypan blue staining (n = 6).
(D) Cell recovery at 48 hr as compared with the cell number used for transfection (i.e., 1.5 · 106 set to 100%). For hCBiPS2
cells, 89 – 22% were recovered at 48 hr after transfection with CAG-eGFP versus 100– 22% in the case of CAG-nRedStar;
for hES3 cells only 34 – 4% were recovered after transfection with the plasmid CAG-eGFP in this assay (n = 5). Color
images available online at www.liebertpub.com/hgtb
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hiPSC lines) were tested. The application of up to 20 lg of
total, circular plasmid DNA per electroporation approach
resulted in balanced cell viability and transgene expression
as depicted in Fig. 1B–D. At 48 hr postelectroporation we
found 44– 5% eGFPpos (n = 7) and 63– 13% nRedStarpos
(n = 7) cells for the iPSC line hCBiPS2, 18 – 3% eGFPpos
(n = 3) and 38 – 1% nRedStarpos (n = 6) cells for hFF1-iPS4,
and 38– 4.8% eGFPpos cells for the ESC line hES3 (n= 6)
(Fig. 1B). Regarding the cell viability directly after elec-
troporation, only marginal differences were observed
between (1) dissociation-only controls (which included
virtually no dead cells in the trypan blue assay and were set
to 100% viability in Fig. 1C), (2) cells that were electro-
porated without DNA (98– 3% hCBiPS2 and 97 – 6% hES3
viability), and cells that received plasmid DNA (96 – 8%
hCBiPS2 and 95 – 1% hES3 viability). Next, the number of
viable cells recovered at 48 hr posttreatment was compared
with the number of cells initially used per electroporation
approach (i.e., always 1.5 · 106 = 100%). For hCBiPS2 this
recovery rate was 132 – 19% in electroporated controls that
received no DNA, 100– 22% after CAG-nRedStar transfec-
tion, and 89– 22% after CAG-eGFP transfection (Fig. 1D).
For hES3 the recovery rate at 48 hr was substantially lower,
that is, 43– 17% for non–DNA electroporated controls and
34– 4% after CAG-eGFP transfection (Fig. 1D), suggesting
their higher sensitivity to the protocol.
One-step generation of stable multitransgenic clones
To test the possibility of generating stable multitransgenic
hPSC clones in a one-step procedure (see schematic sum-
mary of the protocol in Fig. 2A), cells were coelectroporated
with various vector combinations. All experiments included
the vector aMHCneoPGKhygro (the only plasmid entailing
constitutive hygromycin resistance, which was used for
clone selection) together with one additional fluorescence
reporter plasmid (either CAG-eGFP or CAG-rNIS-nVenus;
see vector structure in Fig. 1A) or two additional plasmids
(CAG-eGFP and CAG-nRedStar), aiming at establishing
triple-transgenic cell lines. According to the electroporation
FIG. 2. Schema and timeline for the efficient generation of multitransgenic hPSC clones. (A) hPSCs used for transgenic
modification were cultured under standard feeder-based culture conditions without the necessity for feeder-free preadap-
tation. For transfection cultures were dissociated into single cells and 1.5 · 106 cells were applied per individual electro-
poration approach. Cells were seeded onto Matrigel and 2–3 days posttreatment the transfection efficiency was monitored
and hygromycin-based clone selection was initiated. After 7–10 days resistant colonies became visible. On day 14 colonies
were picked and expanded. (B) Efficiency of antibiotic-resistant clone generation from hCBiPS2 per electroporation
approach coapplying three vectors (aMHCneoPGKhygro, CAG-eGFP, and CAG-nRedStar). On average, 74– 23 independent
colonies were generated per 1.5· 106 cells, whereof 16– 6 appeared to be eGFPpos (*30% of all hygromycin-resistant clones),
4– 2 were nRedStarpos (*6%), and 6– 3 colonies (*10%) expressed both fluorescence markers, that is, eGFPpos/nRedStarpos
(n = 5). (C) Efficiency of antibiotic-resistant colony generation from hES3 cells per electroporation approach coapplying
two vectors (aMHCneoPGKhygro, CAG-eGFP). On average, 14– 4 independent colonies were generated per 1.5· 106
cells whereof 2 – 2 appeared eGFPpos (n = 5). Color images available online at www.liebertpub.com/hgtb
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approach using 1.5 · 106 hCBiPS2 cells, on average, 74– 23
microscopically distinguishable hygromycin-resistant colo-
nies were recovered (n= 5; Fig. 2B and Table 1) at 7–10
days after initiation of hygromycin selection, resulting in an
efficiency of *5· 10-5 (Table 1). The efficiency of forming
hygromycin-resistant colonies was similar for the hiPSC lines
hHSC_F1285_T-iPS2 (up to *2 · 10 - 5) and hFF1-iPS4
(*1 · 10- 5), and the hESC line I3 (*3· 10- 5; Table 1).
However, for hES3 the average number of hygromycin-
resistant colonies was 14 – 4 (n = 5, Fig. 2C; efficiency,
*1 · 10- 5; Table 1) and thus*5-fold lower compared with
hCBiPS2, putatively reflecting the lower recovery of hES3
cells at 48 hr postelectroporation (Fig. 2D), that is, before
initiation of antibiotic selection.
Another interesting observation was made on three-
plasmid–transfected hCBiPS2 cells. Despite the equimolar
transfection with nRedStar- and eGFP-encoding plasmid
DNA (note that the plasmids were also equivalent in size
and structure; Fig. 1) and in contrast to the higher transient
transfection efficiency with CAG-nRedStar (Fig. 1B), the
average number of eGFPpos colonies (among all hygromycin-
resistant ones) was significantly higher than the number of
nRedStarpos colonies, that is, 16– 6 GFPpos versus 4– 2
nRedStarpos (Fig. 2B and Table 1). We further found that,
although eGFP and nRedStar were encoded on two inde-
pendent plasmids, the average number of 6 – 3 double-
fluorescent eGFPpos/nRedStarpos colonies found in this assay
was even higher than the number of 4– 2 colonies expressing
nVenuspos only (Table 1). For three-plasmid–transfected
hFF1-iPS4 and I3 cells an equivalent pattern was observed.
Despite the higher transient transfection efficiency with
CAG-nRedStar (see Fig. 1B for hFF1-iPS4; data not shown
for I3) and equimolar transfection with nRedStar and eGFP
plasmids, eGFPpos colonies were only recovered after hygro-
mycin selection (Table 1).
To establish stable multitransgenic hPSC lines, colonies
were manually picked from Matrigel-coated dishes about 2
weeks after electroporation and subsequently transferred to
feeder-based cultures (Fig. 2A and Fig. 3A and D), where-
upon further hygromycin selection was omitted. Resulting
clones were expanded for four or five passages before re-
analysis of genomic transgene(s) integration and expression.
The genomic integration of the selection vector aMHC-
neoPGKhygro was assessed by PCR (Fig. 3B). Clones from
which all of the three tested vector-specific fragments (re-
presenting key functional elements of the vector; Supple-
mentary Fig. S2) could be amplified (*50% of all clones
tested; n= 59) were analyzed by Southern blotting (Fig. 3C),
using respective restriction endonucleases and a NeoR gene-
specific hybridization probe. Southern blot analysis con-
firmed and expanded the PCR results by demonstrating the
presence of one or two copies of the transgene, respectively,
in all expected clones (Fig. 3C). Applying alternative re-
striction enzymes and an eGFP gene-specific hybridization
probe, we have further demonstrated the genomic integra-
tion of the cotransfected plasmid CAG-eGFP (Fig. 3C). The
hybridization pattern suggests that three of these represen-
tative clones had two copies of the CAG-eGFP plasmid
integrated, whereas one clone apparently exhibited a single
integration event.
However, loss of fluorescence marker expression oc-
curred in*20% of picked clones during the first*3 weeks
of cultivation; eGFP expression remained more stable
compared with nRedStar, tallying with the higher number of
initially eGFPpos colonies recovered after hygromycin se-
lection in our approach (Table 1). Remaining fluorescence-
expressing clones were further passaged four or five times,
stored, and termed transgenic cell lines thereafter.
Multitransgenic cell lines remain pluripotent
and express typical pluripotency markers
Transgenic hPSC lines showed characteristics of their
parental cell lines (Supplementary Fig. S1) regarding their
proliferation characteristics (equivalent splitting interval
and ratio; data not shown) and colony morphology (Fig. 3D,
Fig. 4A, and Fig. 5A). As demonstrated by flow cytometry
the mean fluorescence intensity remained stable in most
established cell lines tested for eGFP expression for up to 23
passages after clonal selection. In rare cases, however,
homogeneous fluorescence expression turned into a mosaic-
like expression pattern, as exemplified in the flow cytometry-
based histogram in Fig. 3E. Notably, no apparent karyotypic
abnormalities were identified when two representative lines
were tested at passage 17 after clone isolation, as exempli-
fied in Fig. 3F. Transgenic lines also showed the expected
expression patterns of the pluripotency-associated genes
OCT4, TRA-1-60, SSEA3, and SSEA4 as demonstrated by
immunocytology (Fig. 4A). To show maintenance of the
differentiation potential, we applied a standard embry-
oid body (EB)-based protocol to test the general multi-
lineage differentiation. Immunocytology on EB outgrowth
on day 21 of differentiation revealed the presence of de-
rivatives of all three germ layers expressing endodermal
(a-fetoprotein [AFP] and SOX17), mesodermal (cardiac
troponin T), and ectodermal (b3-tubulin) marker proteins
(Fig. 4B).
Maintenance of transgene expression
on differentiation
During EB-induced differentiation downregulation of
CAG promoter-controlled fluorescence expression was ob-
served to some extent. Whereas the amount of eGFPpos cells
was in the same range in established lines in the pluripo-
tent state (98 – 0.3%; Fig. 5), the proportion of transgene-
expressing cells declined in a transgenic line-dependent
manner, ranging from 53– 4.5% (strongest preservation) to
7 – 1.3% (highest downregulation) on day 14 of differenti-
ation (Fig. 5A and B). This phenomenon was generally
observed for all fluorescence reporters tested. The compar-
ative analyses of three double-transgenic lines, which all
resulted from transfection with the same vector combination
(CAG-eGFP plus aMHCneoPGKhygro), in Fig. 5B support
the notion that the issue was transgenic line-related, likely
reflecting the influence of different genomic integration
sites and possibly varying copy numbers of the transgene(s)
as well. Of note, differentiated derivatives of a triple-
transgenic line (resulting from aMHCneoPGKhygro, CAG-
eGFP, and CAG-nRedStar transfection; Fig. 6A) showed a
highly stable nRedStar/eGFP expression level of 95– 1.9%
double-positive cells for at least 14 days of differentiation,
with detection of some intermingled cells that were positive
for either one or the other fluorescence marker only (Fig. 6B
and C).
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FIG. 3. Characterization of multitransgenic colonies and hiPSC lines derived therefrom. (A) Light and fluorescence
microscopic appearance of a primary eGFPpos hCBiPS2 cell colony (highlighted by white arrow) on day 10 after co-
transfection with plasmids aMHCneoPGKhygro and CAG-eGFP (i.e., after 7 days of hygromycin selection). Scale bar:
100lm. (B) Established (picked and expanded) eGFPpos clones were analyzed for the integrity of the selection vector
aMHCneoPGKhygro by PCR using primers specific to three individual vector elements. As shown in this gel,*50% of all
clones tested (n= 59) showed only partial integration of the plasmid. Those were excluded from further analysis. (C) Southern
blot analysis of several transgenic clones revealed differences in copy numbers of the transgenes eGFP (representative of
CAG-eGFP, left) and neoR (representative of aMHCneoPGKhygro, right). Lanes representing DNA from nontransfected
control cells are marked with an asterisk. (D) To establish stable clones (and subsequently transgenic cell lines), respective
colonies were individually picked, transferred to feeder cells, and acquired typical hPSC morphology. Depicted is a repre-
sentative eGFP-expressing colony of a transgenic cell line 12 passages after clone picking. (E) Analysis of five established
hCBiPS2 aMHCneoPGKhygro_CAG-eGFP (CAG-eGFP) transgenic cell lines by flow cytometry. Four lines showed ho-
mogeneous eGFP expression with only slight shifts in their median expression intensity (peak of the bell curve) whereas one
line (designated hCBiPS2 CAG-eGFP10; black line) showed a mosaic pattern, whereby a part of the cell population showed no
expression (overlay with nontransgenic control shown in the gray histogram). (F) Exemplary karyotype analysis of two
transgenic cell lines revealed no chromosomal abnormalities at passage 17 after isolation of the initial clones. The depicted
karyogram represents the cell line hCBiPS2 CAG-eGFP2. Color images available online at www.liebertpub.com/hgtb
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Efficient transgene-based cardiomyocyte enrichment
As an example of the practical application of the technique,
three aMHCneo/eGFPpos double-transgenic lines were tested
for the ability to enrich hiPSC-derived cardiomyocytes (CMs)
based on the expression of aMHC promoter-dependent
neomycin resistance. The cardiac differentiation efficien-
cies were equivalent between all transgenic lines tested
(i.e., induction of *22–33% cardiac troponin T [cTnT]-
positive CMs, shown in Fig. 7A) and to nontransgenic
parental controls as well (data not shown). For CM en-
richment addition of G418 was started after the appearance
of beating foci (*days 9–11 of differentiation). Quantifi-
cation of enriched CM populations by immunocytological
staining specific to cTnT (counterstained with DAPI to
visualize cell nuclei; Fig. 7B) revealed > 90% cTnTpos
cells. Similar to nonselected, differentiated cells (*6–13%
of cTnTpos/eGFPpos CMs; Fig. 7A) a mixed pattern of
eGFPhigh, eGFPlow, and GFPneg cells was observed in
G418-selected CMs (Fig. 7C), suggesting that transgene
silencing was apparently not cell type (i.e., cardiomyo-
cyte) specific, but seems to occur somewhat stochastically
in individual cells on differentiation, whereby the over-
all incidence of eGFP expression silencing apparently
varies between individual transgenic cell lines, as out-
lined previously.
Noninvasive cell tracking
To provide a second practical approach for the applica-
tion of our method, we assessed the expression of the rat
sodium iodide symporter (rNIS) transgene as a tool for
noninvasive cell tracking in large animal models in situ and
potentially in vivo. Toward this end hCBiPS2 clones car-
rying two plasmids encoding four functional transgenes
were generated. These included the plasmid aMHCneoPGK-
hygro enabling, first, clonal selection and, second, cardio-
myogenic enrichment, as discussed previously (Fig. 7). The
cointroduced bicistronic vector CAG-rNIS-nVenus encodes
the transmembrane protein rNIS. Endogenous expression of
the symporter is almost exclusively restricted to the thyroid
FIG. 4. Multitransgenic cells display typical hPSC morphology, retain expression of pluripotency markers, and differ-
entiate into derivatives of all three germ layers. (A) As exemplified for the cell line hCBiPS2 aMHCneoPGKhygro_CAG-
eGFP2 (CAG-eGFP2) in passage 21 homogeneous staining of cell colonies for pluripotency associated markers OCT4,
SSEA-3, SSEA-4, and TRA-1-60 (in red; eGFP expression in green; DAPI-stained nuclei in blue) was observed. Scale bars:
100 lm. (B) 21 days after induction of EB-based differentiation of this cell line immunocytological analysis revealed the
expression of markers representative of endoderm (a-fetoprotein [AFP] and SOX17), mesoderm (cardiac troponin T
[cTnT]), and ectoderm (b3 tubulin). Scale bars: 100 lm. Color images available online at www.liebertpub.com/hgtb
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gland; its expression results in the active uptake of iodide
isotopes in transgenic cells, which can then be monitored
via SPECT or positron emission tomography (PET) after
transplantation (Templin et al., 2012). Finally, established
cell lines expressed nVenus (Fig. 8A) as a cytological
marker to facilitate the detection of injected donor cells in
histological tissue sections after termination. Expression of
rNIS was analyzed in three transgenic hCBiPS2 lines via
qRT-PCR and the relative level of transgene expression was
compared with a nontransfected hCBiPS2 control (Fig. 8B).
For functional testing rNISpos-hCBiPS cells were labeled by
incubation with the iodide isotope 123I followed by catheter-
based intramyocardial cell injection into explanted pig
hearts to simulate a clinically applicable route of cell ad-
ministration. The cells were injected into the anterior wall of
the left ventricle and monitored by SPECT-CT, allowing the
detection of 123I-prelabeled cells at the site of transplanta-
tion (Fig. 8C). Notably, successful cell tracing was possible
through a dissected pig chest that had been placed above the
injected heart to mimic signal attenuation in vivo. For con-
firmation of the SPECT-CT imaging results tissue biopsies
were collected at the sites of injection and analyzed by
immunohistology. Indeed, nVenuspos hCBiPS cells were
detected along the presumed injection canal within the
myocardial tissue, which was demarcated by cTnT-specific
staining (Fig. 8D).
Discussion
The ability to genetically modify human PSCs is essential
to fully exploit their potential for in vitro assay develop-
ment, disease modeling, tissue engineering, and ultimately
in regenerative medicine. For this reason substantial efforts
have been invested to establish more efficient protocols for
transgenic hPSC line generation (Costa et al., 2005, 2007;
Braam et al., 2008a,b, 2010; Xu et al., 2008b). Development
of improved electroporation devices has facilitated these
efforts.
In this study, we have combined and optimized protocols
for single-cell dissociation of hPSCs (Olmer et al., 2010;
Zweigerdt et al., 2011) with prominent advantages pro-
vided by the Neon transfection system resulting in a fast
and relative efficient protocol, which is directly applica-
ble to conventional feeder-based cultures and does not
require time-consuming preadaptation to feeder-free cul-
tures. Another key element of progress in our work is the
FIG. 5. Maintenance of CAG promoter-controlled transgene expression on differentiation is transgene line dependent. (A)
Phase-contrast and fluorescence microscopy images of eGFP expression in the transgenic cell line hCBiPS2 CAG-eGFP2 at
the undifferentiated stage (left), after spontaneous differentiation induced by EB-formation on day 7 (middle), and in an EB
outgrowth on day 14 (right). Scale bars: 100lm. (B) Graph depicting the quantitative analysis of three independent cell
lines at the same respective differentiation stages by flow cytometry, revealed a general but differential, cell line-dependent
decrease in the proportion of eGFPpos cells (‘‘silencing’’ of transgene expression). Color images available online at
www.liebertpub.com/hgtb
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straightforward generation of double- and triple-transgenic
clones, that is, stably expressing transgenes encoded on two
or three independent plasmids, based on the antibiotic-based
selection encoded on one of these vectors, only.
An efficient transfection protocol, which was successfully
applicable to five independent hPSC lines including three
hiPSC lines, all established from different somatic cell
sources (see Materials and Methods for details), builds the
basis of our approach. This is notable given the observed
heterogeneity of hiPSC lines with respect to electroporation-
based transfection (Cahan and Daley, 2013). Apart from the
effects of vector structure (i.e., type and arrangement of
promoter and reporter transgenes), a transient transfection
efficiency of up to *45% for eGFP and *65% for nRed-
Star was observed for hiPSC lines whereas *40% eGFP
positivity was observed for hES3. This is significantly
higher compared with previous reports for electroporation
(2– 0.4%), nucleofection (16– 3.6%), and lentiviral trans-
duction (25– 4.8%) (Cao et al., 2010) and equivalent to
results observed for the Neon transfection system by others
investigators (Moore et al., 2010).
Cell viability postelectroporation was also relatively high
in our protocol and subsequently enabled the robust recov-
ery of antibiotic-resistant colonies. For instance, an average
number of *80 hygromycin-resistant colonies was ob-
served after transfection of 1.5 · 106 hCBiPS2 cells, using
FIG. 6. Fluorescence re-
porter expression is mainly
preserved during differentia-
tion in a triple-transgenic
hiPSC line. (A) Stable ex-
pression of cytoplasmic eGFP
and nuclear RedStar in undif-
ferentiated cells of the triple-
transgenic line hCBiPS2
aMHCneoPGKhygro_CAG-
eGFP-nRedStar6 (CAG-
eGFP-nRedStar6). Depicted
is a phase-contrast (left) and
fluorescence image (right) of
a representative colony in
passage 8 after clone picking.
Scale bars: 100lm. (B)
Fluorescence images of dif-
ferentiated cells from the
same line on day 14 of dif-
ferentiation. Although both
fluorescence reporters were
still coexpressed in the vast
majority of the differentiated
cells, a minority of cells lost
either eGFP or nRedStar ex-
pression (white arrows). The
graph in (C) depicts the flow
cytometry-based quantification
of single- and double-positive
cells in the pluripotent state
(top) and at different time
points after induction of dif-
ferentiation. Color images
available online at www
.liebertpub.com/hgtb
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FIG. 7. Genetic enrichment
of hiPSC-derived cardio-
myocytes (CMs) and main-
tenance of fluorescence
reporter gene expression. (A)
Dot plots depicting flow cy-
tometric analysis of two
differentiated but not CM-
enriched cell lines (i.e.,
hCBiPS2 CAG-eGFP2 [left]
and hCBiPS2 CAG-eGFP6
[right]) revealed the induc-
tion of *33.5% cardiac tro-
ponin T-positive (cTnTpos)
CMs (top row in the left plot)
whereby 29.1% of the cells
expressed eGFP and 13.1%
of the total cell population
appeared to be double posi-
tive for cTnT and GFP, re-
spectively. Slightly lower
cardiomyogenic differentia-
tion efficiency and thus a
different proportion of
cTnTpos versus cTnTneg cells,
was observed for the line
hCBiPS2 CAG-eGFP6 (right).
(B) The line hCBiPS2 CAG-
eGFP2 was differentiated in
an EB-based approach in
serum-freemedium, leading to
various cell lineages, among
them beating CM clusters, as
depicted by the cTnT (in red;
DAPI stained nuclei, blue)-
specific stain of fixed cells
in the top and bottom left pic-
tures. G418 (neomycin ana-
log) selection resulted in a
highly enriched cardiac cell
population with almost all
cells positively stained for
cTnT (right). (C) Partial
eGFP fluorescence reporter
silencing was observed in un-
selected cells (left) and in
G418-enriched CMs as well
(right), resulting in mosaic-
like expression patterns. Scale
bars: 100 lm. Color images
available online at www
.liebertpub.com/hgtb
148 SCHWANKE ET AL.
the two-vector combination of CAG-nRedStar and aMHC-
neoPGKhygro, thus resulting in a total colony formation
efficiency of*5.3 · 10- 5 (Table 1). Approximately 25% of
these colonies (*19 on average; Table 1) also expressed
nRedStar, resulting in an efficiency of 1.3 · 10 - 5 double-
transgenic colonies; an equivalent value of 1.2 · 10- 5 was
also detected for eGFP-expressing colonies observed after
cotransfection of CAG-eGFP and aMHCneoPGKhygro
(Table 1).
Thus, our efficiency for the genomic integration and ex-
pression of two independent plasmids was equivalent or
moderately lower compared with efficiencies achieved after
FIG. 8. Transgenic rNIS expression enables in situ imaging of multitransgenic hiPSCs in a pig heart. (A) Fluorescence
microscopy of a colony of an established multitransgenic hCBiPS2 line (aMHCneoPGKhygro_CAG-rNIS-nVenus2; CAG-
rNIS2) coexpressing the rat sodium iodide symporter (rNIS; see graph in B) and the nuclear yellow GFP variant Venus
(nVenus, green). (B) Three independent transgenic hCBiPS2 CAG-rNIS lines were analyzed by qRT-PCR for rNIS
transgene expression. rNIS expression was normalized to cellular b-Actin and respective expression levels are shown
relative to non-transfected control cells (left column). (C) Iodine isotope 123I prelabeled hCBiPS2 CAG-rNIS6 cells were
injected ex vivo into explanted pig hearts and placed under a dissected pig chest in order to simulate in vivo imaging after
clinical cell transplantation. After the injection of 5 · 106 prelabeled cells, the heart was scanned with a Hybrid SPECT-CT.
Depicted are SPECT-CT images in the coronal and sagital plane demonstrating tracer signal at the site of cell injection. (D)
Detection of injected cells using an anti-GFP antibody (cross reacting with the yellow GFP variant Venus, green). On
respective microtome sections the heart muscle tissue was visualized by anti-cTnT staining (in red) and cell nuclei were
counter stained by DAPI (in blue). nVenuspos cells were detected along the presumed injection channel. Scale bars: 100lm.
Notably, fixation and immunhistological treatment of the tissue led to a more cytoplasmatic staining pattern of the otherwise
nuclear Venus that is in contrast to the strictly nucleus-restricted pattern in viable cells as shown in A. Color images
available online at www.liebertpub.com/hgtb
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single-vector transfection by Moore and colleagues
(4.9 · 10- 5; Moore et al., 2010) and Braam and colleagues
(up to 1.9 · 10- 4, also using the CAG promoter; Braam
et al., 2008b). However, these published studies critically
relied on the adaptation of hPSCs to feeder-free conditions
before genetic manipulation, with the known disadvantages
of increased time requirements and the enrichment of po-
tentially abnormal cell clones that better tolerate these cul-
ture conditions. Our method is therefore also considerably
faster and requires only *14 days until the appearance of
multitransgenic colonies when starting with conventional
feeder-based cultures. Another feature of our strategy is the
fact that feeder cells were dispensable in the antibiotic se-
lection phase. This makes the protocol adaptable to any type
of antibiotic resistance transgene and independent of the
availability of resistant feeder cells.
We noted, however, that the efficiency of fluores-
cence marker expression (encoded on separate vectors) of
hygromycin-resistant colonies was *5- to 10-fold lower
(range, 0.1–0.2 · 10- 5) for the other cell lines tested (Table
1). These results correlate with the lower seeding efficiency
and/or cell viability that was observed for these cell lines at
48 hr postelectroporation, thus resulting in lower cell num-
bers per well before the initiation of antibiotic-based colony
selection (see Fig. 1D for hES3 cells). Following our strat-
egy shown here, further cell line-specific adaptations of
protocol parameters, that is, by modifying the dissociation
conditions before electroporation, the DNA concentration,
and the cell-seeding density after the treatment, should
overcome this issue.
Using the hCBiPS2 line, we have further observed an
efficiency of 0.4 · 10- 5 for the formation of hygromycin-
resistant colonies coexpressing eGFP and nRedStar, thus
representing three-plasmid (triple)-transgenic cell lines
(Table 1). To the best of our knowledge this is the first study
demonstrating the possibility of achieving stable coin-
troduction of multiple plasmid vectors into hPSCs with only
one of these plasmids carrying an antibiotic resistance
marker. We acknowledge, however, that our coapplied
vectors carried constitutively expressed fluorescence mark-
ers, which clearly facilitated the identification of (multi-)
transgene-expressing colonies.
We have intentionally used common eukaryotic expres-
sion vectors without specific elements that might support
their episomal replication and segregation such as scaffold/
matrix attachment regions (S/MARS) (Argyros et al., 2011;
Wade-Martins, 2011) or autonomous functional elements
present on human artificial chromosomes (HACs; Mandegar
et al., 2011). This fact makes the episomal persistence of
plasmids in transgenic colonies and cell lines derived
thereof extremely unlikely. In one study we have also ap-
plied PCR to monitor the persistence of plasmid vectors
(which were of equivalent structure to vectors applied here)
after transient hPSC transfection by electroporation (Har-
tung et al., 2013). We found that high plasmid levels per-
sisted for *12 hr in hPSCs but that plasmids were almost
undetectable 48 hr after cell transfection even by PCR, ar-
guing against their prominent episomal replication, if any.
Here, we have also performed Southern blot analysis of
single or multitransgenic cell lines that were passaged up to
14 times after clone isolation (notably in the absence of any
antibiotic-based selection pressure) before genomic DNA
was isolated and analyzed. The respective hybridization
patterns unequivocally confirmed the stable integration of
the respective plasmid vectors in the genome.
Despite the discussed cell line-dependent variability of
the method’s efficiency, our approach generally worked
with all five hPSC lines tested. However, by focusing on the
stable transgene introduction into the parental cell line
hCBiPS2, we have also observed a remarkable transgene
dependency. Such disparities were apparently reporter gene
dependent and, more specifically, seem to be related to the
subcellular localization of respective fluorescence trans-
genes. Whereas 40% of cytoplasmic eGFP-expressing
clones gave rise to stable fluorescent protein-expressing cell
lines (i.e., 24 lines of 59 clones tested; Table 1), only 23% (3
of 13) of nVenus lines were generated and no stable
nRedStar only-expressing lines could be established, despite
serious attempts (0 of 33); notably 1 stable eGFP/nRedStar-
coexpressing line (1 of 10) was successfully generated
(Table 1 and Fig. 6). These results were unexpected, par-
ticularly in the light of the *2-fold higher transient ex-
pression levels found for nRedStar compared with eGFP as
depicted for hCBiPS2 and hFF1-iPS4 in Fig. 1B. Whether
the RedStar protein itself or its intended nuclear localization
underlies these observations requires further side-by-side
comparison of different reporters expressed in the same
subcellular compartments.
Our results confirm previous findings (Liew et al., 2007)
demonstrating that the CAG promoter-controlled reporter
gene expression remained stable in the pluripotent state in
established hiPSC lines during long-term cultivation, that is,
for up to 23 passages, in contrast to retroviral and lentiviral
vectors (Pannell and Ellis, 2001; Ellis and Yao, 2005). We
further found that the expression of one or even two fluo-
rescence reporters in transgenic lines did not interfere with
their pluripotency and multilineage differentiation potential.
This point is worth highlighting because culture adaptation,
which is usually required during the generation of transgenic
cell lines, has been reported to alter culture and differentiation
characteristics (Enver et al., 2005; Catalina et al., 2008).
Besides stable transgene expression in undifferentiated
hPSCs, maintenance of transgene expression in differenti-
ated derivatives is of special interest for various applica-
tions. The undesired but frequently observed silencing of
transgenes on differentiation is known to depend on the
vector design and especially the promoter used.
Using the CAG promoter, we have analyzed several
transgenic cell lines regarding the expression of eGFP or
coexpression of eGFP/nRedStar after induction of differ-
entiation. As previously reported for other plasmids or
lentiviral vectors using this promoter (Hong et al., 2007;
Xia et al., 2007; Chen et al., 2011), we found for three
transgenic lines tested some level of silencing and subse-
quently a mosaic-like expression of eGFP in differentiated
progenies (Figs. 5 and 7A). This was also true in aMHC
promoter-neoR-enriched cardiomyocytes (Fig. 7C). Whe-
ther the presence of different cardiomyocyte subtypes (i.e.,
pacemaker-, atrial-, or ventricular-like cells), the hetero-
geneous myocyte maturation grade, or somewhat sto-
chastic silencing (i.e., in some daughter cells but not in
others) accounts for these results rather than cell type (i.e.,
cardiomyocyte)-specific events that occur during differ-
entiation requires further investigation.
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Although the CAG promoter offers a valuable tool for
transgene expression in hPSCs in the pluripotent state and
on differentiation, it is well established that promoter
methylation, which might be integration site specific, is a
main cause of transgene silencing (Alexopoulou et al.,
2008). Interestingly, studies have shown that ubiquitous
chromatin-opening elements (UCOEs) can strongly reduce
promoter DNA methylation and thereby prevent epigenetic
transgene silencing in mouse and human PSCs and their
progenies (Pfaff et al., 2013; Ackermann et al., 2014).
Thus, the strategy might support stable transgene expres-
sion controlled by ubiquitous and lineage-specific pro-
moters independent of the (random) genomic integration
site.
Finally, we have tested the overexpression of an rNIS
symporter as a proof-of-concept for cell tracking in a clin-
ically relevant animal model of heart damage, namely the
pig. Constitutive nVenus/rNIS-expressing undifferentiated
hiPS cells were injected intramyocardially into an isolated
pig heart ex vivo. We showed that our transgenic cells can be
detected by SPECT-CT imaging in situ, and subsequently
the presence of injected cells was confirmed by means of a
second transgene, that is, nVenus, on histological tissue
sections. These are important steps for the efficient, un-
equivocal monitoring of donor cell survival and distribution
in large animal models, which is a key issue in the field
(Chang et al., 2006; Yang, 2012). First experiments apply-
ing respective cell lines generated by our method for lon-
gitudinal monitoring of hPSC engraftment in a pig
myocardial infarct model in vivo have already been per-
formed (Templin et al., 2012).
In summary, we provide a novel method enabling the fast
and relative efficient generation of multitransgenic hPSC
lines expressing transgenes located on independent plasmids
with only one antibiotic resistance marker. Our improved
technology also has potential to support the targeting of
transgenes into specific loci via homologous recombination
in future experiments.
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